Masimo Corp Stock Price, News & Analysis

Masimo (NASDAQ: MASI) is set to release its second quarter 2021 financial results on July 27, 2021, after market close. The results will be discussed in a conference call at 1:30 p.m. PT, led by CEO Joe Kiani and CFO Micah Young. Participants can register for the call via a provided link to receive dial-in details. Masimo specializes in medical technology, focusing on innovative monitoring solutions that improve patient outcomes. Its Masimo SET® technology has been validated in over 100 studies, showcasing its effectiveness in clinical settings.

Masimo (NASDAQ: MASI) has released findings from a study in the Journal of Critical Care showing that two parameters from Masimo SedLine^®—Patient State Index (PSi) and Suppression Ratio (SR)—can accurately predict neurological outcomes and long-term survival in post-cardiac arrest ICU patients. The study indicates that low values of PSi and SR correlate with higher mortality rates at 180 days, establishing their effectiveness as prognostic tools. This may influence treatment plans and care decisions in critical care settings.

Masimo (NASDAQ: MASI) has received FDA 510(k) clearance for its Radius Tº™, a wearable thermometer for continuous, noninvasive body temperature monitoring. Suitable for patients aged five and older, it features Bluetooth connectivity for easy integration with Masimo's monitoring solutions and smartphone applications. The device supports hospital automation and streamlines workflows with its single-patient use design. Radius Tº offers enhanced accuracy compared to traditional thermometers, providing critical temperature data for both clinicians and consumers. This clearance marks a significant expansion in Masimo's temperature monitoring capabilities.

Masimo (NASDAQ: MASI) announced a study in the Turkish Journal of Medical Sciences demonstrating that the Oxygen Reserve Index (ORi) can guide oxygenation during one-lung ventilation (OLV) in thoracic surgery. Conducted on 103 patients, the study concluded that ORi-guided oxygen titration might reduce hospital stays and enhance patient safety by minimizing hyperoxic conditions. Findings indicated a significantly shorter duration of OLV and lower FiO₂ values in ORi-monitored groups. ORi, however, is not yet FDA-cleared for use in the U.S.

Masimo (NASDAQ: MASI) announced its management will participate in the UBS Global Healthcare Virtual Conference on May 26, 2021, at 2:00 p.m. Eastern Time. A live webcast will be accessible on the Masimo website, with a replay available afterward.

Masimo is a global medical technology company specializing in advanced monitoring systems and solutions aimed at improving patient outcomes and reducing healthcare costs. Its innovative technologies, including Masimo SET^®, are widely used in hospitals globally, showcasing significant advantages over traditional methods.

Masimo (NASDAQ: MASI) has released a study demonstrating the benefits of its Patient SafetyNet™ system. Conducted by researchers at Nippon Medical School, the study revealed that the implementation of this technology led to a 61.3% reduction in nursing workload for postoperative respiratory assessments. Nurses reported increased satisfaction with remote monitoring, rising from 78.7% to 89.3% pre- to post-implementation. The findings suggest that continuous monitoring of respiratory rates and oxygen saturation enhances patient safety after general anesthesia.

Spacelabs Healthcare, a division of OSI Systems, has announced an extension of its partnership with Masimo to integrate advanced patient monitoring technologies into Spacelabs multi-parameter monitors. The collaboration will include SET pulse oximetry, NomoLine capnography, and other innovative monitoring solutions.

Both companies aim to enhance patient care by providing deeper insights into patients' physiological conditions, thereby improving outcomes for healthcare providers and patients alike.

Masimo (NASDAQ: MASI) announced a study published in the Journal of Anesthesia & Clinical Research demonstrating the effectiveness of its O3^® Regional Oximetry in monitoring septic shock patients. The research, conducted by Medical College Kolkata, found significant correlations between O3 trends and hemodynamic variables, highlighting its potential as a noninvasive predictor of mortality. The study monitored 40 patients, revealing significant differences in cerebral rSO₂ between survivors and non-survivors over 72 hours. This suggests O3 may provide valuable insights for managing critically ill patients.

Masimo (NASDAQ: MASI) announced a study published in the Journal of Applied Physiology evaluating the Pleth Variability Index (PVi^®) for predicting preload responsiveness in patients receiving nasal high-flow therapy. Conducted by Dr. Marina García-de-Acilu and colleagues, the research involved 20 ICU patients with acute respiratory failure. PVi demonstrated high sensitivity (91.7%) and specificity (87.8%) in identifying preload responders. While the findings suggest potential clinical utility, further validation is needed. The study indicates that PVi may not be universally applicable across all patients treated with high-flow therapy.